MT1B

Across TCGA pan-cancer cohorts, MT1B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MT1B data layer compared with 17 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MT1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MT1B expression acts as an unfavorable survival marker.

OV and LUAD are the cancer types where MT1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.165	0.541	.004	18	view →
LUAD	OS	Median	All	0.269	0.813	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MT1B–OV (DFS)

Open the OV breakdown →